Eyeworld Supplements

SUPPLEMENT TO EYEWORLD DAILY NEWS, MAY 6, 2023 | Supported by Alcon 3 Refer to page 8 for Important Product Information about the Alcon products described in this supplement. Ophthalmologist chooses Clareon for his own cataract surgery Randy Epstein, MD W hen Randy Epstein, MD, was ready for cataract sur- gery in his second eye, he had one goal. He wanted excellent uncorrected distance vision with a clear visual axis. Dr. Epstein said after seeing the "consistently excellent outcomes and visual satisfaction" that the Clareon IOL platform (Alcon) provided for his patients, he chose the Clareon Monofo- cal IOL for his surgery. "I was hoping when Alcon introduced the product that it would be as good as they said it would be," he said. While Dr. Epstein said he does a lot of refractive cataract surgery using premium IOLs, he opted for monovision with his first eye and thus wanted to prioritize clear distance vision with his second eye. He highlights the importance of lens selection based on patient lifestyle and expectations. "With my personality, I would have an extremely low tolerance for any issues. I didn't want to accept any optical tradeoffs in order to obtain intermedi- ate vision in addition to distance vision." As a cataract surgeon, Dr. Epstein said he was "universally pleased" with the results of the AcrySof IOL platform (Alcon). When Alcon shifted its IOL portfolio to the new Clareon IOL plat- form, Dr. Epstein said that one of the purposes was the elimination of a "small but highly publicized issue: glistenings." Dr. Epstein added that he never had a patient who had any visually significant optical issues related to glistenings in an AcrySof IOL; however, he was excited to shift his lens offerings to this advanced biomaterial. Clareon, an aspheric hydrophobic acrylic IOL made from a patented biomaterial (acrylate/methacrylate copolymer), 1 was FDA approved in 2020 and began its commercial launch in the U.S. in March 2022. 2 Clareon is a "glistening-free" material that in in vitro examinations had among the lowest levels of haze and subsurface nanoglistenings compared with other IOLs. 3 * In addition to a material change, Clareon features a proprietary edge design to help reduce glare and posterior capsule opacification. 4 Clareon maintains many of the other attributes of the AcrySof, such as STABLEFORCE Haptics for axial and rotational stability. 5,6 The Clareon platform is the result of decades of innovation and advanced manufacturing techniques. 2 Four optical designs are available on the Clareon platform, which provides what's considered exceptional clarity (based on in vitro examinations of glistenings, surface haze, and sub-surface nanoglistenings). • Clareon Monofocal IOL: This provides a broad landing zone with 20/20 distance vision and functional intermediate vision. 7,8 • Clareon PanOptix IOL: This delivers a full range of vision —20/20 distance, intermediate, and near vision—as a trifocal IOL. 9,10 **† • Clareon Vivity IOL: This achieves monofocal-quality distance visual acuity with excellent intermediate and functional near vision as a non-diffractive extended depth of focus IOL. 11,12 • Clareon Toric: This includes STABLEFORCE Haptics for rota- tional and axial stability 5,6 The Clareon IOL maintains the high-quality and established benefits that Dr. Epstein experienced with the previous AcrySof IOL platform. He said his patients "have been uniformly pleased with their outcomes [with Clareon IOLs], and I have been pleased with how they perform and how they appear inside the eye." Editors' note: Dr. Epstein is a corneal specialist and chief executive officer of Chicago Cornea Consultants in Chicago, Illinois. He can be contacted at repstein@chicagocornea.com. *Defined as modified Miyata grade 0, <25 mv/mm 2 over 3 years (n=138), and over 9 years (n=20), respectively. **Based on mean value of binocular defocus curve at near, intermediate, and distance at 6 months (n=127). †Snellen VA was converted from logMAR VA. A Snellen notation of 20/20-2 or better indicates a logMAR VA of 0.04 or better, which means 3 or more of the 5 Early Treatment Diabetic Retinopa- thy Study chart letters in the line were identified correctly. References 1. Clareon IOL Directions for Use. 2. Alcon Strengthens Leadership in IOL Innovation with Launch of Clareon Portfolio in the U.S. Press Release. 2022. 3. Werner L, et al. Evaluation of clarity characteristics in a new hydrophobic acrylic IOL in compari- son to commercially available IOLs. J Cataract Refract Surg. 2019;45:1490–1497. 4. Das KK, et al. In vitro and schematic model eye assessment of glare or positive dysphotop- sia-type photic phenomena: Comparison of a new material IOL to other monofocal IOLs. J Cataract Refract Surg. 2019;45:219–227. 5. Alcon internal technical report. Clareon SY60WF Axial Displacement Study at Varied Compres- sions. TDOC-0054028. 2017. 6. Kramer BA, et al. Rotation characteristics of three toric monofocal intraocular lenses. Clin Ophthalmol. 2020;14:4379–4384. 7. Bala C, et al. Multicountry clinical outcomes of a new nondiffractive presbyopia-correcting intraocular lens. J Cataract Refract Surg. 2022;48:136–143. 8. Varma D, et. al. Clinical outcomes of a new non-diffractive presbyopia-correcting intraocular lens from two large confirmatory studies. American Academy of Ophthalmology. Abstract: PA005. 9. Lehmann R, et al. Effectiveness and safety of the Clareon Monofocal intraocular lens: outcomes from a 12-month single-arm clinical study in a large sample. Clin Ophthalmol. 2021;15:1647–1657. 10. Clareon PanOptix Trifocal Hydrophobic Acrylic IOL Model CNWTT0 2021. 11. Clareon Vivity Extended Vision Hydrophobic IOL (CNWET0) Directions for Use. 12. Results from a prospective, randomized, parallel group, subject- and assessor-masked, multisite trial of 107 subjects bilaterally implanted with the AcrySof IQ Vivity IOL and 113 with the AcrySof IQ IOL with 6 months' follow-up.

• Cover